Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 6
Submit an article Journal homepage
314
Views
73
CrossRef citations to date
0
Altmetric
Reviews

Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors. Part I: Nucleoside analogues

Nathaniel A Brown President Antiviral Development LLC, 60 Rolling Lane, Weston, Massachusetts, 02493, USA +1 617 669 4274; +1 781 647 7660; [email protected]
, MD
Pages 709-725 | Published online: 09 May 2009

Bibliography

  • Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-8
  • Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment – finding the right path. Nat Rev Drug Discov 2007;6:991-1000
  • Chemello I, Cavalletto L, Casarin C, et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. Ann Intern Med 1996;124:1058-60
  • Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-81
  • Lau DT, Kleiner DE, Ghany MG, et al. 10-year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998;28:1121-7
  • Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005;41:106-14
  • Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
  • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
  • Hoofnagle JH, Seef LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51
  • Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
  • Houghton M, Weiner AJ, Han JH, et al. Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology 1991;14:381-8
  • Lindenbach BD, Rice CM. Unraveling hepatitis C virus replication from genome to function. Nature 2005;436:933-8
  • Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-7
  • Fukimoto T, Berg T, Ku Y, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996;24:1351-4
  • Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Nat Acad Sci USA 1991;88:3392-6
  • Domingo E, Martinez-Salas E, Sobrino FF, et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance – a review. Gene 1985;40:1-8
  • Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-9
  • Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988;242:1168-71
  • Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988;242:1171-3
  • Ho D. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-1
  • Jacobson IM, Everson GT, Gordon SC, et al. Interim analysis results from a Phase 2 study of telaprevir with pegintereron alfa-2a and ribairin in treatment-naïve subjects with hepatitis C. Hepatology 2007;46(4 Suppl 1):315A
  • Hezode C, Ferenci P, Dusheiko GM, et al. PROVE-2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa-2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis. Hepatology 2007;46(4 Suppl 1):268A
  • Kwo P, Lawitz E, McCone J, et al. Boceprevir plus peginterferon alfa-2b/ribavirin for treatment of genotype-1 chronic hepatitis C in previously untreated patients: interim results from the HCV SPRINT-1 study. Hepatology 2008;48(4 Suppl):1027A
  • Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002
  • Lawitz EJ, Rodriguez-Torres M, Muir A, et al. 28 days of the hepatitis C protease inhibitor, in combination with PEG-interferon α-2a and ribavirin, is well-tolerated and demonstrates robust antiviral effects. Gastroenterology 2006;131:950-1
  • Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-77
  • Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999;6:937-43
  • Bresanelli S, Tomei L, Roussel A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Nat Acad Sci USA 1999;96:13034-49
  • Ago H, Adachi T, Yoshida A, et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct Fold Des 1999;7:1417-26
  • Carroll SS, Olsen DB. Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 2006;6:17-29
  • Gordon CP, Keller PA. Control of hepatitis C: a medicinal chemistry perspective. J Med Chem 2005;48:1-20
  • De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-18
  • Tomei L, Altamura S, Paonessa G, et al. HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the NS5B polymerase. Antiviral Chem Chemother 2005;16:225-45
  • Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Invest Drugs 2007;8:614-34
  • Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1091-8
  • Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:185-91
  • Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9
  • Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients: a randomized, double-blind, controlled trial. Ann Int Med 1997;126:355-63
  • O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31
  • Walensky RP, Paltiel AD, Losina E, et al. The survival benefit of AIDS treatment in the United States. J Infect Dis 2006;194:11-19
  • Vermund SH. Millions of lives saved with potent antiretroviral drugs in the United States: a celebration, with challenges. J Infect Dis 2006;194:1-5
  • Sommadosi JP, La Colla P. 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections. US20040077587A1; 2004
  • Sommadosi JP, La Colla P. Methods and compositions for treating hepatitis C virus. US6914054B2; 2005
  • Carroll SS, Tomassini JE, Bosserman M, et al. Inhibition of hepatitis C virus replication by 2'-modified nucleoside analogs. J Biol Chem 2003;278:11979-84
  • Pierra C, Amador A, Benzaria S, et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine. J Med Chem 2006;49:6614-20
  • Benzaria S, Bardiot D, Bouisset T, et al. 2'-C-methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication. Antiviral Chem Chemother 2007;18:225-42
  • Standring DN, Lanford R, Wright T, et al. NM283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. J Hepatol 2003;38(Suppl 2):S3
  • Murakami E, Bao H, Ramesh M, et al. Mechanism of activation of β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 2007;51:503-9
  • Cretton-Scott E, Perigaud C, Peyrottes S, et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. J Hepatol 2008;48(Suppl 2):S220
  • Olsen D, Eldrup AB, Bartholomew L, et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004;48:3944-52
  • Carroll S, Davies ME, Handt L, et al. Robust suppression of viral replication by a nucleoside in chimpanzees infected with hepatitis C virus. Hepatology 2006;44(4 Suppl 1):535A
  • Klumpp K, Leveque V, Le Pogam S, et al. The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J Biol Chem 2006;281:3793-9
  • Klumpp K, Smith D, Brandl M, et al. Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4'-azidocytidine) with enhanced oral bioavailability [abstract 21]. Antiviral Res 2007;74:A35
  • Press release, Hoffman-La Roche, Inc.; Oct. 21, 2008
  • Furman PA, Wang P, Niu C, et al. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C. Hepatology 2008;48(4 Suppl):1161A
  • Afdhal N, Godofsky E, Dienstag J, et al. Final Phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 2004;40(4 Suppl. 1):276A
  • Roberts S, Cooksley G, Dore G, et al. Results of a Phase 1B, multiple dose study of R1626, a novel nucleoside analog targeting HCV polymerase in chronic HCV genotype 1 patients. Hepatology 2006;44:692A
  • Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007;46(4 Suppl 1):862A
  • Idenix Pharmaceuticals, Inc., press release; 13 July, 2007
  • Rodriguez-Torres M, Afdhal NH, Lawitz EJ, et al. Final results from a Phase IIa pharmacokinetic study of valopicitabine (NM283) and peg-IFN-α2b in patients with genotype 1 chronic hepatitis C. Gastroenterology 2007;132(4 Suppl 2):A778
  • Pockros P, O'Brien C, Godofsky E, et al. Valopicitabine (NM283), alone or with peg-interferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in hepatitis C patients with prior non-response to PegIFN/RBV: week 24 results. Gastroenterology 2006;130(4 Suppl 2):A748
  • Lawitz E, Nguyen T, Younes Z, et al. Clearance of HCV RNA with valopicitabine (NM283) plus peg-interferon in treatment-naïve patients with HCV-1 infection: results at 24 and 48 weeks. J Hepatol 2007;46(Suppl 1):S9
  • Poordad F, Lawitz EJ, Gitlin N, et al. Efficacy and safety of valopicitabine in combination with pegylated interferon-α (peg-IFN) and ribavirin (RBV) in patients with chronic hepatitis C. Hepatology 2007;46(4 Suppl 1):866A
  • Standring DN, Bichko V, Chase R, et al. HCV polymerase (NM107) and protease (boceprevir) inhibitors in combination show enhanced activity and suppression of resistance in the replicon system. Hepatology 2007;46(4 Suppl 1):857A
  • Pockros PJ, Nelson D, Godofsky E, et al. Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (40 KD), with or without ribavirin – interim analysis results of Phase 2a study. Hepatology 2007;46(4 Suppl 1):311A
  • Nelson D, Pockros PJ, Godofsky E. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon alfa-2a (40KD) and ribavirin followed by a further 44 weeks of peginterferon alfa-2a and ribavirin. J Hepatol 2008;48(Suppl 2):S371
  • Lalezari J, Gane E, Rodriguez-Torres M, et al. Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with peg-IFN and ribavirin: interim results of R7128 500 mg BID for 28 days. J Hepatol 2008;48(Suppl 2):S29
  • Gane EJ, Rodriguez-Torres M, Nelson DR, et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: interim results of R7128 1500mg BID with Peg-IFN and ribavirin for 28 Days. Hepatology 2008;48(4 Suppl):1024A
  • Standring D, Lanford R, Cretton-Scott E, et al. Potent antiviral activity of 2nd generation HCV nucleotide inhibitors, IDX-102 and IDX-184, in HCV-infected chimpanzees. J Hepatol 2008;48(Suppl 2):S30
  • Idenix Pharmaceuticals quarterly earnings call transcript; 30 October 2008; accessed at idenix.com
  • Leveque V, Le Pogam S, Kang H, et al. Potency of R1479, active compound derived in vivo from prodrug R1626, demonstrated across HCV genotypes 1-6 in NS5B recombinant enzymes and HCV replicons. J Hepatol 2008;48(Suppl 2):S319
  • Carroll S, Tomassini JE, Bosserman M, et al. Susceptibility of different genotypes of hepatitis C virus to inhibition by nucleoside and non-nucleoside inhibitors. Antiviral Res 2004;62:A83
  • Ludmerer SW, Graham DJ, Boots E, et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 2005;49:2059-69
  • Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73
  • Bartels D, Zhou Y, Zhang E, et al. Natural prevalence of HCV variants with decreased susceptibility to NS3-4A protease and NS5B polymerase inhibitors in treatment-naïve subjects. J Hepatol 2008;48(Suppl 2):S316
  • Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:1-8
  • Le Pogam S, Seshaadri A, Kosaka A, et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Ther 2008;61:1205-16
  • Le Pogam S, Seshaadri A, Kang H, et al. Low level of resistance, low viral fitness and absence of resistance mutations in baseline quasispecies may contribute to high barrier to R1626 resistance in vivo. J Hepatol 2008;48(Suppl 2):S10
  • Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537-44
  • Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral drug therapy inn HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-80
  • Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000;181:946-53
  • Bichko V, La Colla M, Tausek MM, et al. Characterization of NM283 (valopicitabine) resistance profile using the bovine viral diarrhea virus. Hepatology 2005;43(4 Suppl 1):534A
  • Miglaccio G, Tomassini JE, Carroll SS, et al. Characterization of resistance to non-obligate chain-terminating chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 2003;278:49164-70
  • Ali S, Leveque V, Le Pogam S, et al. In vitro selection and characterization of HCV replicons with reduced sensitivity to PSI-6130 [abstract P-263]. 14th International Symposium on Hepatitis C Virus and Related Viruses. September 9-13, 2007. Glasgow, UK
  • Le Pogam S, Seshaadri A, Kosaka A, et al. A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment naïve patients. Hepatology 2007;46(4 Suppl 1):817A
  • McCown M, Rajyaguru S, Symons J, et al. The nucleoside inhibitors R1479, PSI-6130, and NM107 have a higher genetic barrier to resistance than the non-nucleoside inhibitor HCV-796 and the protease inhibitor VX-950 [abstract P-265]. 14th International Symposium on Hepatitis C Virus and Related Viruses. September 9-13, 2007. Glasgow, UK
  • Le Pogam S, Jiang WR, Leveque V, et al. In vitro selected Con 1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006;351:349-59
  • Seiwert SD, Tan H, Blatt LM. Additive to synergistic antiviral effects of an NS3/4A protease inhibitor and an NS5B RNA-dependent RNA polymerase inhibitor (R1479) in an HCV replicon system. J Hepatology 2007;46(Suppl 1):S167

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.